Robert W. Hesslein Sells 1,864 Shares of Foundation Medicine Inc (NASDAQ:FMI) Stock

Foundation Medicine Inc (NASDAQ:FMI) SVP Robert W. Hesslein sold 1,864 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $64.00, for a total value of $119,296.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Foundation Medicine Inc (NASDAQ:FMI) traded up $0.45 during trading on Friday, hitting $73.60. The stock had a trading volume of 195,392 shares, compared to its average volume of 253,921. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.24 and a quick ratio of 2.03. The company has a market cap of $2,680.00, a price-to-earnings ratio of -16.47 and a beta of -0.01. Foundation Medicine Inc has a 12-month low of $18.60 and a 12-month high of $74.85.

Foundation Medicine (NASDAQ:FMI) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.16. The firm had revenue of $42.66 million for the quarter, compared to analyst estimates of $37.99 million. Foundation Medicine had a negative return on equity of 143.18% and a negative net margin of 119.69%. The company’s revenue was up 45.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.90) EPS. analysts expect that Foundation Medicine Inc will post -4.44 EPS for the current year.

Institutional investors have recently made changes to their positions in the company. Teachers Advisors LLC grew its position in Foundation Medicine by 5.7% during the 1st quarter. Teachers Advisors LLC now owns 24,387 shares of the company’s stock worth $786,000 after acquiring an additional 1,316 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in Foundation Medicine by 9.9% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 60,227 shares of the company’s stock worth $2,395,000 after acquiring an additional 5,404 shares during the last quarter. Rhumbline Advisers grew its position in Foundation Medicine by 9.7% during the 2nd quarter. Rhumbline Advisers now owns 16,628 shares of the company’s stock worth $661,000 after acquiring an additional 1,470 shares during the last quarter. State of Wisconsin Investment Board bought a new position in Foundation Medicine during the 2nd quarter worth approximately $437,000. Finally, Bank of New York Mellon Corp grew its position in Foundation Medicine by 1.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 61,597 shares of the company’s stock worth $2,449,000 after acquiring an additional 835 shares during the last quarter. Hedge funds and other institutional investors own 32.66% of the company’s stock.

FMI has been the topic of a number of research analyst reports. BidaskClub upgraded Foundation Medicine from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th. Zacks Investment Research lowered Foundation Medicine from a “buy” rating to a “hold” rating in a research note on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $45.33.

ILLEGAL ACTIVITY NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/28/foundation-medicine-inc-fmi-svp-sells-119296-00-in-stock.html.

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply